We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+46.65%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1B
AUM Growth
+$220M
Cap. Flow
-$11.4M
Cap. Flow %
-1.13%
Top 10 Hldgs %
62.05%
Holding
51
New
6
Increased
3
Reduced
11
Closed
2

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$30.3M
2
CBAY
Cymabay Therapeutics
CBAY
+$12.2M
3
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$11.2M
4
QURE icon
uniQure
QURE
+$8.06M
5
MTNB icon
Matinas BioPharma
MTNB
+$7.34M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$56.5M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10.5M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$10.2M
4
APLS
Apellis Pharmaceuticals
APLS
+$7.72M
5
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$4.96M

Sector Composition

Rank Sector Weight
1 Healthcare 97.66%
2 Materials 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOMX
51
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-201,478
Closed -$723K
1 2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Vivo Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Vivo Capital held 51 positions worth $1B, up 28% from $783M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Vivo Capital's Q1 2019 filing shows 6 new, 3 increased, 11 reduced and 2 closed positions. Its largest new stake was Insmed: 1,170,290 shares worth $34M. The largest sale was Biohaven Pharmaceutical Holding Company Ltd., an estimated $56.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Materials.

  • Vivo Capital's largest Q1 2019 buy was Insmed: 1,170,290 shares worth $34M.
  • Vivo Capital added most to Cymabay Therapeutics in Q1 2019, an estimated $12.2M increase.
  • Vivo Capital's biggest Q1 2019 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $56.5M.
  • Vivo Capital fully exited Arvinas in Q1 2019, selling an estimated $2.69M.
  • Vivo Capital's ten largest holdings make up 62% of its $1B portfolio in Q1 2019.
  • Vivo Capital opened 6 new positions and closed 2 in Q1 2019.
  • Vivo Capital's portfolio value rose 28% quarter-over-quarter to $1B.

Based on Vivo Capital's 13F filing for Q1 2019, filed 14 May 2019.